The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer.
Mol Ther
; 29(6): 1958-1969, 2021 06 02.
Article
en En
| MEDLINE
| ID: mdl-33932597
ABSTRACT
Multiple studies have confirmed that programmed cell death 1/programmed cell death ligand-1 (PD-1/PD-L1) and immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 play pivotal roles in the treatment of numerous tumors. Patients suffering from cancer are provided hope in the form of immunotherapy. In this review, we discuss the finding that high PD-L1 expression is associated with poor clinical outcomes in prostate cancer patients. Some molecules exert their antitumor effects by downregulating PD-L1 expression in prostate cancer. Additionally, we discuss and summarize the important roles played by anti-PD-1/PD-L1 immunotherapy and its combination with other drugs, including chemotherapy and vaccines, in the treatment of prostate cancer.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Biomarcadores de Tumor
/
Antígeno B7-H1
/
Receptor de Muerte Celular Programada 1
/
Antineoplásicos Inmunológicos
Tipo de estudio:
Etiology_studies
/
Prognostic_studies
Límite:
Humans
/
Male
Idioma:
En
Año:
2021
Tipo del documento:
Article